kabutan

ASKA Pharma, Apr-Dec (Cumulative 3Q) Ordinary Profit Decreases by 11%

Mon Feb 2, 2026 3:30 pm JST Earnings

4886 ASKA Pharmaceutical Holdings Co.,Ltd. 【J-GAAP】

Earnings Report

ASKA Pharmaceutical Holdings Co.,Ltd. <4886> [TSE Prime] announced its financial results after the market closed on February 2nd (15:30). The consolidated ordinary profit for the cumulative third quarter of the fiscal year ending March 2026 (April to December) decreased 10.9% from the same period last year to 4.85 billion yen. Progress toward the full-year plan of 6.00 billion yen was 80.9%, below the five-year average of 99.2%.

Based on the cumulative third-quarter performance announced by the company and the unchanged full-year plan, our calculation indicates that the consolidated ordinary profit/loss for the January to March period (4Q) is expected to turn into a profit of 1.14 billion yen (compared to a loss of 0.33 billion yen in the same period last year).

In the most recent three-month period, from October to December (3Q), the consolidated ordinary profit amounted to 2.19 billion yen, an increase of 2.8% compared to the same period last year. However, the operating profit margin decreased from 12.2% in the same period last year to 11.8%.

Kabutan News

Actual Results

Accumulated Results 3rd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Apr - Dec, 2023 48,824 5,526 5,631 6,458 228.1 86.3 Feb 5, 2024 J-GAAP
Apr - Dec, 2024 49,926 5,495 5,446 4,098 144.6 106.6 Feb 3, 2025 J-GAAP
Apr - Dec, 2025 54,486 4,911 4,854 3,904 137.6 80.9 Feb 2, 2026 J-GAAP
YoY +9.1% -10.6% -10.9% -4.7% -4.8%

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2024 31,768 1,986 1,795 2,541 89.6 30 May 12, 2025 J-GAAP
Oct - Mar, 2025 Guidance 35,747 3,351 3,340 2,774 97.7 28 Nov 4, 2025 J-GAAP
YoY +12.5% +68.7% +86.1% +9.2% +9.0%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2024 62,843 6,500 6,522 7,545 266.5 40 May 10, 2024 J-GAAP
Mar, 2025 64,139 5,331 5,107 5,101 180.0 55 May 12, 2025 J-GAAP
Mar, 2026 Guidance 71,000 6,000 6,000 5,000 176.1 55 Nov 4, 2025 J-GAAP
YoY +10.7% +12.5% +17.5% -2.0% -2.2%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Oct - Dec, 2024 17,555 2,150 2,134 1,538 54.3 12.2 Feb 3, 2025 J-GAAP
Jan - Mar, 2025 14,213 -164 -339 1,003 35.4 -1.2 May 12, 2025 J-GAAP
Apr - Jun, 2025 17,641 1,479 1,620 1,244 43.9 8.4 Aug 4, 2025 J-GAAP
Jul - Sep, 2025 17,612 1,170 1,040 982 34.6 6.6 Nov 4, 2025 J-GAAP
Oct - Dec, 2025 19,233 2,262 2,194 1,678 59.1 11.8 Feb 2, 2026 J-GAAP
YoY +9.6% +5.2% +2.8% +9.1% +9.0%

Related Articles